You are here:

  1. NICE
  2. NICE Guidance
  3. Conditions and diseases
  4. Liver conditions
  5. Chronic liver disease

Odevixibat for treating progressive familial intrahepatic cholestasis

  • Highly specialised technologies guidance
  • Reference number: HST17
  • Published:  22 February 2022
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Final evaluation determination
  2. Evaluation consultation: 1
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

History

A list of downloadable documents created during development.

Final evaluation determination

  • Final evaluation determination

  • Final evaluation determination document (PDF 350 KB)

    Published:
    14 January 2022
  • Committee papers (PDF 1.22 MB)

    Published:
    14 January 2022

Evaluation consultation: 1

  • Evaluation consultation: 1

  • Evaluation consultation document (PDF 186 KB)

    Published:
    16 September 2021
  • Committee papers (PDF 5.21 MB)

    Published:
    16 September 2021
  • Public committee slides (PDF 2.2 MB)

    Published:
    16 September 2021

Invitation to participate

  • Consultation document (PDF 499 KB)

    Published:
    02 March 2021
  • Equality Impact Assessment (Guidance development) (PDF 118 KB)

    Published:
    02 March 2021
  • Final scope (PDF 166 KB)

    Published:
    02 March 2021
  • Final stakeholder list (PDF 183 KB)

    Published:
    02 March 2021

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

  • Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

  • Draft scope post referral (PDF 224 KB)

    Published:
    19 February 2021
  • Draft matrix of consultees and commentators post referral (PDF 186 KB)

    Published:
    19 February 2021